Activation of PPARβ/δ Causes a Psoriasis-Like Skin Disease In Vivo
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Psoriasis is one of the most frequent skin diseases world-wide. The disease impacts enormously on affected patients and poses a huge financial burden on health care providers. Several lines of evidence suggest that the nuclear hormone receptor peroxisome proliferator activator (PPAR) beta/delta, known to regulate epithelial differentiation and wound healing, contributes to psoriasis pathogenesis. It is unclear, however, whether activation of PPARbeta/delta is sufficient to trigger psoriasis-like changes in vivo. METHODOLOGY/PRINCIPAL FINDINGS: Using immunohistochemistry, we define the distribution of PPARbeta/delta in the skin lesions of psoriasis. By expression profiling, we confirm that PPARbeta/delta is overexpressed in the vast majority of psoriasis patients. We further establish a transgenic model allowing inducible activation of PPARbeta/delta in murine epidermis mimicking its distribution in psoriasis lesions. Upon activation of PPARbeta/delta, transgenic mice sustain an inflammatory skin disease strikingly similar to psoriasis, featuring hyperproliferation of keratinocytes, dendritic cell accumulation, and endothelial activation. Development of this phenotype requires the activation of the Th17 subset of T cells, shown previously to be central to psoriasis. Moreover, gene dysregulation in the transgenic mice is highly similar to that in psoriasis. Key transcriptional programs activated in psoriasis, including IL1-related signalling and cholesterol biosynthesis, are replicated in the mouse model, suggesting that PPARbeta/delta regulates these transcriptional changes in psoriasis. Finally, we identify phosphorylation of STAT3 as a novel pathway activated by PPARbeta/delta and show that inhibition of STAT3 phosphorylation blocks disease development. CONCLUSIONS: Activation of PPARbeta/delta in the epidermis is sufficient to trigger inflammatory changes, immune activation, and signalling, and gene dysregulation characteristic of psoriasis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sano, S., Chan, K. S., Carbajal, S., Clifford, J., Peavey, M., Kiguchi, K., Itami, S., Nickoloff, B. J., & DiGiovanni, J. (2005) · Nature Medicine · doi:10.1038/nm1162 · Cited by 752 · cited 2×
“STAT3 is phosphorylated in psoriasis [34], as well as in a”
BackgroundPPAR : a dagger in the heart of the metabolic syndrome
Barish, G. D. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27955 · Cited by 641
Michalik, L., Desvergne, B., Tan, N. S., Basu-Modak, S., Escher, P., Rieusset, J., Peters, J. M., Kaya, G., Gonzalez, F. J., Zakany, J., et al. (2001) · The Journal of Cell Biology · doi:10.1083/jcb.200011148 · Cited by 406
Critical roles of PPARβ/δ in keratinocyte response to inflammation
Tan, N. S., Michalik, L., Noy, N., Yasmin, R., Pacot, C., Heim, M., Flühmann, B., Desvergne, B., & Wahli, W. (2001) · Genes & Development · doi:10.1101/gad.207501 · Cited by 398
The Metabolic Syndrome and Inflammation
Sutherland, J. P., McKinley, B., & Eckel, R. H. (2004) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2004.2.82 · Cited by 243 · cited 1×
“Specifically, factors such as TNFa which are known to directly induce PPARb/d expression are increased in the chronic inflammation accompanying metabolic syndrome [40].”
BackgroundGeneral nature of the STAT3-activated anti-inflammatory response.
El Kasmi, K. C., Holst, J., Coffre, M., Mielke, L., de Pauw, A., Lhocine, N., Smith, A. M., Rutschman, R., Kaushal, D., Shen, Y., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.11.7880 · Cited by 225
Peroxisome Proliferator-Activated Receptors Increase Human Sebum Production
Trivedi, N. R., Cong, Z., Nelson, A. M., Albert, A. J., Rosamilia, L. L., Sivarajah, S., Gilliland, K. L., Liu, W., Mauger, D. T., Gabbay, R. A., et al. (2006) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700336 · Cited by 184 · cited 1×
“It is known that ligand-mediated activation of PPARb/d in the sebaceous gland triggers sebocyte differentiation [28,29] and delivery of sebum to the skin [30], containing lipoxygenase-derived bioactive lipids that can bind and activate the AhR, such as LXA4 or 5,6-DiHETE [31,32].”
BackgroundChong, H. C., Tan, M. J., Philippe, V., Tan, S. H., Tan, C. K., Ku, C. W., Goh, Y. Y., Wahli, W., Michalik, L., & Tan, N. S. (2009) · Journal of Cell Biology · doi:10.1083/jcb.200809028 · Cited by 107
Cited by
Strategies and Approaches of Targeting STAT3 for Cancer Treatment
Furtek, S. L., Backos, D. S., Matheson, C. J., & Reigan, P. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.5b00945 · Cited by 347
Suárez-Fariñas, M., Li, K., Fuentes-Duculan, J., Hayden, K., Brodmerkel, C., & Krueger, J. G. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.184 · Cited by 305
Physiological functions of peroxisome proliferator-activated receptor β
Neels, J. G., & Grimaldi, P. A. (2014) · Physiological Reviews · doi:10.1152/physrev.00027.2013 · Cited by 161
Biology and Therapeutic Applications of Peroxisome Proliferator- Activated Receptors
P. Menendez-Gutierrez, M., Roszer, T., & Ricote, M. (2012) · Current Topics in Medicinal Chemistry · doi:10.2174/156802612799436669 · Cited by 62
Identification of a novel PPARβ/δ/miR‐21‐3p axis in UV‐induced skin inflammation
Degueurce, G., D'Errico, I., Pich, C., Ibberson, M., Schütz, F., Montagner, A., Sgandurra, M., Mury, L., Jafari, P., Boda, A., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201505384 · Cited by 47
Metadata
- Authors
- Romanowska, M., Reilly, L., Palmer, C. N. A., Gustafsson, M. C. U., & Foerster, J.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2010-03-16
- Volume
- 5
- Issue
- 3
- Pages
- e9701
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W1963851023
- Cited by
- 86
- References
- 8
- FWCI
- 4.80
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.